Mizzou Pins Aging Muscle Loss on Nerve Signal Breakdown — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- W. David Arnold and University of Missouri-Columbia collaborators found that the neuromuscular junction — where nerves tell muscles to contract — becomes less reliable with age, contradicting the long-held assumption that this connection remains stable or even improves.
- The communication breakdown was linked to lower levels of the NaV1.4 protein, which helps muscle fibers respond to nerve signals, in both humans and animal models.
- The findings shed light on sarcopenia, the age-related decline in muscle strength and function that affects nearly half of adults older than 80.
- In an animal model, partially inhibiting the ClC-1 protein — using an approach developed by Denmark's NMD Pharma — made aging muscles more responsive to nerve signals and increased muscle strength, suggesting the failure point is reversible.
- Arnold previously served as an investigator in a multicenter clinical trial of ignaseclant, NMD Pharma's experimental ClC-1 inhibitor, in patients with Charcot-Marie-Tooth disease; topline findings were presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference.
- The study, "Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition," was published in The Journal of Clinical Investigation and involved collaborators from Denmark, Scotland, Saudi Arabia, and India, plus neuromuscular junction specialist Hiroshi Nishimune, who joined the Mizzou lab from Tokyo.
- Rather than rebuilding lost muscle or neurons, the experimental approach aims to make existing muscle fibers more responsive to the nerve messages they already receive.
Why it matters: Sarcopenia affects nearly half of adults over 80, yet prior researchers had assumed the neuromuscular junction stays reliable — possibly even improves — with age. Mizzou's finding inverts that assumption and points to a target (ClC-1) that NMD Pharma is already testing in humans for Charcot-Marie-Tooth disease, meaning a sarcopenia therapy could repurpose an existing clinical-stage drug rather than start from scratch.
Ask SkimNews
